These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16944408)

  • 1. Noradrenaline might enhance assertive human social behaviours: an investigation in a flatmate relationship.
    Tse WS; Bond AJ
    Pharmacopsychiatry; 2006 Sep; 39(5):175-9. PubMed ID: 16944408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reboxetine promotes social bonding in healthy volunteers.
    Tse WS; Bond AJ
    J Psychopharmacol; 2003 Jun; 17(2):189-95. PubMed ID: 12870566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difference in serotonergic and noradrenergic regulation of human social behaviours.
    Tse WS; Bond AJ
    Psychopharmacology (Berl); 2002 Jan; 159(2):216-21. PubMed ID: 11862352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of noradrenergic re-uptake inhibition on memory encoding in man.
    Papps BP; Shajahan PM; Ebmeier KP; O'Carroll RE
    Psychopharmacology (Berl); 2002 Jan; 159(3):311-8. PubMed ID: 11862364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No influence of noradrenaline manipulation on acute exercise-induced increase of brain-derived neurotrophic factor.
    Goekint M; Heyman E; Roelands B; Njemini R; Bautmans I; Mets T; Meeusen R
    Med Sci Sports Exerc; 2008 Nov; 40(11):1990-6. PubMed ID: 18845978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reboxetine-induced increase of accumbal dopamine efflux is inhibited by l-propranolol: a microdialysis study with freely moving rats.
    Mizoguchi N; Saigusa T; Aono Y; Sekino R; Takada K; Oi Y; Ueda K; Koshikawa N; Cools AR
    Eur J Pharmacol; 2008 Dec; 601(1-3):94-8. PubMed ID: 18996113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of reboxetine, a noradrenaline reuptake inhibitor, on the plasma noradrenaline response to a cold pressor test in healthy volunteers.
    Kelly CB; McAree S; Cooper SJ; Stevenson M
    J Psychopharmacol; 2002 Dec; 16(4):333-6. PubMed ID: 12503832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonergic intervention affects both social dominance and affiliative behaviour.
    Tse WS; Bond AJ
    Psychopharmacology (Berl); 2002 May; 161(3):324-30. PubMed ID: 12021836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of repeated treatment with reboxetine on the central alpha1-adrenergic system.
    Rogóz Z; Kolasiewicz W
    Pol J Pharmacol; 2001; 53(6):663-7. PubMed ID: 11985343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noradrenergic stimulation and motor performance: differential effects of reboxetine on movement kinematics and visuomotor abilities in healthy human subjects.
    Wang LE; Fink GR; Dafotakis M; Grefkes C
    Neuropsychologia; 2009 Apr; 47(5):1302-12. PubMed ID: 19428394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in cortisol response to reboxetine.
    Tse WS; Bond AJ
    J Psychopharmacol; 2005 Jan; 19(1):46-50. PubMed ID: 15671128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of reboxetine on autonomic and cognitive functions in healthy volunteers.
    Siepmann M; Mück-Weymann M; Joraschky P; Kirch W
    Psychopharmacology (Berl); 2001 Sep; 157(2):202-7. PubMed ID: 11594447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
    Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
    Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers.
    Boonleang J; Panrat K; Tantana C; Krittathanmakul S; Jintapakorn W
    Clin Ther; 2007 Apr; 29(4):703-10. PubMed ID: 17617293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial.
    Sarris J; Kavanagh DJ; Deed G; Bone KM
    Hum Psychopharmacol; 2009 Jan; 24(1):41-8. PubMed ID: 19090505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance.
    Schroeder C; Tank J; Boschmann M; Diedrich A; Sharma AM; Biaggioni I; Luft FC; Jordan J
    Circulation; 2002 Jan; 105(3):347-53. PubMed ID: 11804991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers.
    Garcia JM; Polvino WJ
    Oncologist; 2007 May; 12(5):594-600. PubMed ID: 17522248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.